Results 241 to 250 of about 126,260 (296)

Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data

Clinical Endocrinology, EarlyView.
ABSTRACT Background Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) has emerged as a potential strategy to improve resectability and reduce morbidity in ...
Alexandra Dorman, Genady Shendler, Anton Warshavsky, Nidal Muhanna, Gilad Horowitz, Liyona Kampel Furman, Shahaf Shilo, Ben‐Zion Joshua, Eran Alon, Eric Remer, Galit Avior, Avi Khafif, Orit Gutfeld, Elena Izkhakov, Jobran Mansour, Inbar Finkel   +15 more
wiley   +1 more source

Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient. [PDF]

Front Oncol
Jian X, Liu G, Yu S, Sheng J.
europepmc   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Exostosin 1/exostosin 2-associated membranous nephropathy in undifferentiated connective tissue disease: a case report and literature review. [PDF]

BMC Nephrol
Ye H, Jiang X, Wu B, Xie X, Zheng Z.
europepmc   +1 more source

Estimating the risk of cardiovascular outcomes and all‐cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate United Kingdom Prospective Diabetes Study Outcomes Model version 2 (UKPDS‐OM2) cardiovascular risk estimates for people with type 2 diabetes using TECOS and EXSCEL data. Materials and methods We compared model‐simulated and TECOS and EXSCEL observed event rates for the composite outcome of cardiovascular death, myocardial ...
Ruth L. Coleman, Amanda I. Adler, Philip M. Clarke, Darren K. McGuire, Rury R. Holman   +4 more
wiley   +1 more source

Successful treatment of severe systemic lupus erythematosus with anifrolumab: a single-center observational study. [PDF]

Reumatologia
Wisłowska M, Szczęsny P, Wroński J, Bonek K.   +3 more
europepmc   +1 more source

Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Continuous glucose monitoring (CGM) has emerged as a complementary and more dynamic method for evaluating glycemic control in people with diabetes. Relevant studies examining the association between CGM parameters, including time in range (TIR), glycemic variability (GV), and time in tight range (TITR), and diabetic nephropathy, retinopathy ...
Lilian Anagnostopoulou, Alexandros L. Liarakos, Ioannis Ntanasis‐Stathopoulos, Alexandros Briasoulis, Anastasios Tentolouris   +4 more
wiley   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism. [PDF]

Sci Rep
Ahmed RM, Soliman AR, Mohammed A.
europepmc   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source